Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac Safety of PLD vs Doxorubicin in Early Breast Cancer
NCT03949634Phase 3Unknown
- Sponsor
- Fudan University
- Start
- Sep 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Duomeisu in breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Cardiotoxicity at 2 years. Status: unknown.
02
Drugs
Duomeisu
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03949634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03949634.